Related Experiment Videos
Cardiac hypertrophy and hypertension
1Cardiac Department, Stobhill Hospital NHS Trust, Glasgow, UK.
Insights
Left ventricular hypertrophy (LVH) in hypertension is a known cardiovascular risk. While advances improve understanding and management, the impact of LVH regression on overall risk requires further study.
Area of Science:
- Cardiology
- Hypertension Research
- Clinical Medicine
Background:
- Left ventricular hypertrophy (LVH) is a significant cardiovascular risk factor in hypertensive patients.
- Recent years have seen advances in understanding LVH pathophysiology, detection, and management, including hypertrophy regression.
- Key factors contributing to myocyte hypertrophy include stretch, angiotensin II, and sympathetic nervous system stimulation.
Purpose of the Study:
- To review the current understanding of left ventricular hypertrophy (LVH) in hypertension.
- To discuss advances in the pathophysiology, detection, and management of LVH.
- To explore the mechanisms of increased mortality and the role of LVH regression.
Main Methods:
- Literature review of epidemiological, pathophysiological, and clinical studies on LVH in hypertension.
- Comparison of diagnostic methods for LVH, specifically echocardiography and ECG.
- Analysis of factors contributing to myocyte and fibroblast proliferation.
Main Results:
- Trophic factors like angiotensin II and sympathetic stimulation drive myocyte hypertrophy.
- Aldosterone and angiotensin contribute to fibroblast proliferation.
- Echocardiography is more reliable than ECG for LVH detection, though both are complementary.
Conclusions:
- Mechanisms of increased mortality in LVH patients, including ischemia, dysfunction, and arrhythmias, are under investigation.
- Optimal blood pressure control is crucial.
- The specific impact of LVH regression on morbidity and mortality requires further clinical trials.
Abstract:
The epidemiology of left ventricular hypertrophy (LVH) in hypertension has been extensively studied and its importance as a cardiovascular risk factor is established. Significant advances in recent years have also occurred in pathophysiology, detection of LVH, and in management including regression of hypertrophy. Advances in pathophysiology have demonstrated that a number of trophic factors such as stretch, angiotensin II and stimulation of the sympathetic nervous system contribute towards the hypertrophy of the myocyte. In addition, it is important to emphasise factors such as aldosterone and angiotensin which contribute towards the proliferation of fibroblasts. The mechanisms involved in the increased mortality in patients with left ventricular hypertrophy remain to be determined, but myocardial ischaemia, left ventricular dysfunction and a propensity to ventricular arrhythmias have all been studied in detail. Echocardiography is a more reliable method for detecting LVH than ECG, but these investigations should be regarded as complementary rather than one being performed to the exclusion of the other. It remains unclear as to whether regression of LVH specifically contributes to a reduction in overall cardiovascular risk, but the key point seems to be optimal control of blood pressure, and only with further clinical trials will the exact impact of regression of LVH on morbidity and mortality be known.